Search - Prime Therapeutics - Portal

540 Results for GLP-1 Pipeline Update

Endpoint News: Almost all patients quit weight loss shots within two years, analysis finds

Endpoint News

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Weight-loss drugs didn't curb health costs within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Washington Post: Weight-loss drugs are supposed to be forever. Until they run out.

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
NBC News: Most people stop using Wegovy and Ozempic after 2 years, analysis finds

NBC News: Patients weren't asked why they quit taking the weight loss drugs

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Summer 2025 Issue: Clinical Insights – MASH

Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic...

Login Portals

Compliance / Legal

Company

© 2026 Prime Therapeutics LLC